Design Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Design Therapeutics, Inc. (DSGN) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $1.07 million for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2021-08-09
- Design Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-06-30 was -$301.00K, a 159.60% decline year-over-year.
- Design Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2021-03-31 was $1.38M.
- Design Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-06-30 was $505.00K.
- Design Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-03-31 was -$354.00K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month |
|---|---|---|
| 2021-06-30 | -$301.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $1.07M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $1.38M 10-Q · filed 2021-05-10 | |
| 2020-06-30 | $505.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $151.00K 10-Q · filed 2021-08-09 |
| 2020-03-31 | -$354.00K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |